DEXACORT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Sep 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXACORT is a metered-dose inhaled aerosol small-molecule corticosteroid approved in 1962 for respiratory indications. The exact therapeutic indications are not fully specified in available data, but the inhalation route and aerosol formulation suggest pulmonary/asthma or COPD-related use. As a corticosteroid, it functions through anti-inflammatory mechanisms targeting glucocorticoid receptors.
LOE Approaching
With LOE approaching and zero linked job openings, the brand is in managed decline phase with minimal hiring activity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, DEXACORT offers minimal career growth opportunity and represents a sunset portfolio asset. Roles on this product are primarily defensive (managing market share decline) rather than growth-oriented.
Brand ManagerField Sales Representative
Worked on DEXACORT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.